Obesity Forum®: Individualizing Obesity Care and Challenging Cases
This activity is supported by educational grants from Lilly and Novo Nordisk, Inc.
Click Here to Manage Email Alerts
Overview
Provider Statement
This continuing medical education activity is provided by 
Support Statement
This activity is supported by educational grants from Lilly and Novo Nordisk, Inc.
Activity Description
Obesity is an increasingly prevalent chronic condition associated with substantial risks of morbidity and mortality. It is also a risk factor for some of the leading causes of preventable death, including cardiovascular disease, stroke, type 2 diabetes mellitus, sleep apnea, gallbladder disease, osteoarthritis, and certain types of cancer. With prevalence continuing to escalate, it is predicted that 1 in 2 Americans will have obesity by 2030. Among the groups at risk for obesity are youths aged 2 to 19 years—of whom 19.3% are estimated to have obesity. Currently, underdiagnosis and undertreatment of obesity are frequent due to shortcomings in patient evaluation, uncertainty regarding approaches that support adherence to behavioral and lifestyle modifications, and a lack of thorough knowledge concerning the efficacy and safety of pharmacologic and surgical interventions. Patients with overweight or obesity often have multiple health concerns and may see several providers; therefore, a multidisciplinary management approach is required. This activity aims to provide health care professionals with guidance on the appropriate use of therapies as well as strategies for delivering individualized care to patients of any age with overweight or obesity via interprofessional strategies.
Target Audience
The intended audience for this activity is family medicine physicians, internists, endocrinologists, pharmacists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with overweight and obesity.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Utilize interprofessional strategies to treat overweight and obesity, including shared decision-making and consideration of patient preferences/perspectives.
- Select “high-risk” patients with obesity and related complications/comorbidities who may benefit from further evaluation and treatment for weight loss.
- Employ recent clinical evidence regarding the pharmacological management of overweight and obesity in children and adolescents.
- Summarize the long-term pharmacological management of obesity, including clinical evidence for weight regain after cessation of medication.
Activity Chair
Robert F. Kushner, MD, MS, FACP, FTOS, DABOM
Professor, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Director, Center for Lifestyle Medicine
Northwestern Medicine
Chicago, IL
Faculty
Holly Herrington, MS, RD, LDN, CDCES
Advanced Clinical Dietitian
Center for Lifestyle Medicine and Bariatric Surgery
Northwestern Memorial Hospital
Chicago, IL
Ania M. Jastreboff, MD, PhD, DABOM
Associate Professor of Medicine, Endocrinology & Metabolism
Associate Professor of Pediatrics, Pediatric Endocrinology
Director, Weight Management and Obesity Prevention, Yale Stress Center
Co-Director, Yale Center for Weight Management
Yale University School of Medicine
New Haven, CT
Scott Kahan, MD, MPH, FTOS, DABOM
Director, National Center for Weight and Wellness
Johns Hopkins Bloomberg School of Public Health
Washington, DC
Patricia Nece, JD
Patient Advocate
Chair of the Board of Directors
Obesity Action Coalition
Alexandria, VA
Donna H. Ryan, MD, FACP, FTOS
Professor Emerita
Pennington Biomedical Research Center
Louisiana State University
Baton Rouge, LA
Christopher D. Still, DO, FACP, FTOS, DABOM
Professor of Medicine
Department of Clinical Sciences
Geisinger Commonwealth School of Medicine
Medical Director, Center for Nutrition & Weight Management
Director, Geisinger Obesity Institute
Geisinger Health System
Danville, PA
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Jennifer Frederick, PharmD, BCPS
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity enables the participant to earn up to 2.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participants who opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.
This program is acceptable for 2.0 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-22-051-H01-P, effective 12/31/2022. This is a knowledge-based activity, and there is no fee to attend.
Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor® within 30 days.
This activity is approved for 2.0 contact hour(s) of continuing education (which includes 1.42 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 22115892. This activity was planned in accordance with AANP Accreditation Standards and Policies.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours credit for completing this program.
This enduring material is approved for 1 year from the date of original release, December 31, 2022, to December 30, 2023.
How to Participate in This Activity and Obtain CME Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 6 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, Contact Hour Certificate, or Statement of Continuing Pharmacy Education.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Activity Chair and Faculty report the following relevant financial relationship(s)
Holly Herrington, MS, RD, LDN, CDCES
No relevant financial relationships to disclose.
Ania M. Jastreboff, MD, PhD, DABOM
Advisor: Boehringer Ingelheim, Intellihealth, Lilly, Novo Nordisk, Pfizer, Rhythm Pharmaceuticals, Weight Watchers
Individual Stocks and Stock Options: Intellihealth
Multi-center Trials: Lilly, Novo Nordisk, Rhythm Pharmaceuticals
Scott Kahan, MD, MPH, FTOS, DABOM
Consultant: Gelesis, Lilly, Novo Nordisk, Pfizer, Vivus
Robert F. Kushner, MD, MS, FACP, FTOS, DABOM
Consultant: Altimmune, Lilly, Novo Nordisk, Weight Watchers
Independent Research Contractor: Epitomee
Patricia Nece, JD
Consultant: Novo Nordisk
Donna H. Ryan, MD, FACP, FTOS
Advisor: Altimmune, Calibrate, Gila Therapeutics, Lilly, Novo Nordisk, Real Appeal, Wondr Health, YSOPIA, Zealand
Consultant: Amgen, Epitomee, IFA Celtic, Scientific Intake, Roman, Zealand
Speaker Contracted by Ineligible Company: Novo Nordisk
Independent Research Contractor: Calibrate, Epitomee, Roman, Scientific Intake
SELECT Steering Committee: Novo Nordisk
Christopher D. Still, DO, FACP, FTOS, DABOM
Consultant: Novo Nordisk
Speaker Contracted by Ineligible Company: Novo Nordisk
Independent Research Contractor: Ethicon Endo-Surgery, Novo Nordisk
Planners/Reviewers report the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Jennifer Frederick, PharmD, BCPS
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com